An Evaluation of Lipid Profile among Patients with Type 2 Diabetes Mellitus using Total Cholesterol (TC), Triglycerides (TG), High-Density Lipoprotein Cholesterol (HDL-C), and Low-Density Lipoprotein Cholesterol (LDL-C)
DOI:
https://doi.org/10.31149/ijimm.v4i9.3000Keywords:
Lipid Profile, Type 2 Diabetic, Patient, Cholesterol (Tc), Triglycerides (Tg), High-Density, Lipoprotein Cholesterol (Hdl-C), Low-Density, Lipoprotein Cholesterol (Ldl-C)Abstract
The study sought to evaluate the lipid profile among type 2 diabetic patients using total cholesterol (TC), triglycerides (TG), high-density lipoprotein cholesterol (HDL-C), and low-density lipoprotein cholesterol (LDL-C) in type 2 diabetic patients. In carrying out the study, a comparative cross-sectional design was adopted. The study population consisted of one hundred (100) diagnosed type 2 diabetic patients and one hundred (100) apparently healthy, age- and sex-matched non-diabetic individuals who served as controls. All participants were aged between 30 and 70 years. Ten (10) mL of venous blood samples were collected from each participant after overnight fast using standard aseptic procedures and distributed into appropriate tubes for the determination of fasting plasma glucose (FPG), glycated hemoglobin (HbA1c), insulin, lipid profile, and oxidative stress markers. Serum and plasma were prepared by centrifugation at 3000 rpm for 10 minutes, while whole blood was used for selected analyses. The samples were analyzed using standard laboratory methods. Data obtained were analyzed using Statistical Package for Social Sciences (SPSS) version 25.0. Results were expressed as Mean ± Standard Deviation. The test of significance was determined using independent samples t-test, while Pearson correlation analysis was used to assess relationships between variables, with p < 0.05 considered statistically significant. There were significantly higher mean levels of total cholesterol, triglycerides, and low-density lipoprotein cholesterol (p = 0.000 for all) in Type 2 diabetic patients (6.60 ± 0.57 mmol/L, 2.68 ± 0.52 mmol/L, and 4.42 ± 0.59 mmol/L, respectively) when compared to controls (4.16 ± 0.42 mmol/L, 1.16 ± 0.19 mmol/L, and 2.35 ± 0.46 mmol/L, respectively). There was a significantly lower mean level of high-density lipoprotein cholesterol (p = 0.000) in Type 2 diabetic patients (1.02 ± 0.14 mmol/L) compared to controls (1.54 ± 0.17 mmol/L). The study concluded that Type 2 diabetes is frequently accompanied by abnormalities in lipid metabolism, which may manifest as elevated TC, TG, and LDL-C levels together with reduced HDL-C levels. One of the recommendations made was that Lipid profile testing, including TC, TG, HDL-C, and LDL-C, should be carried out routinely among type 2 diabetic patients to facilitate early detection and management of lipid abnormalities.
References
[1] K. R. Feingold and C. Grunfeld, “Diabetes and dyslipidemia,” in Endotext, K. R. Feingold et al., Eds. South Dartmouth, MA, USA: MDText.com, Inc., 2023. [Online]. Available: NCBI Bookshelf
[2] S. Kalra and N. Raizada, “Dyslipidemia in diabetes,” Indian Heart Journal, vol. 76, no. 1, pp. 1–8, 2024, doi: 10.1016/j.ihj.2023.12.005.
[3] R. J. Perry, V. T. Samuel, K. F. Petersen, and G. I. Shulman, “The role of hepatic lipids in hepatic insulin resistance and type 2 diabetes,” Nature, vol. 510, no. 7503, pp. 84–91, 2020.
[4] A. Rawshani, A. Rawshani, S. Franzén, B. Eliasson, A. Svensson, A. M. Sattar, M. Rosengren, and A. Gudbjörnsdottir, “Mortality and cardiovascular disease in type 1 and type 2 diabetes,” New England Journal of Medicine, vol. 376, no. 15, pp. 1407–1418, 2017.
[5] T. A. Zelniker, S. D. Wiviott, I. Raz, K. Im, E. L. Mosenzon, M. F. Cahn, A. L. Bhatt, M. Leiter, M. McGuire, B. Wilding, and E. Braunwald, “SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: A systematic review and meta-analysis of cardiovascular outcome trials,” The Lancet, vol. 393, no. 10166, pp. 31–39, 2019.
[6] American Diabetes Association, “Standards of medical care in diabetes—2023,” Diabetes Care, 2023.
[7] A. M. T. Gusti, S. Y. Qusti, E. M. Alshammari, E. A. Toraih, et al., “Antioxidants-related superoxide dismutase (SOD), catalase (CAT), glutathione peroxidase (GPx), glutathione-S-transferase (GST), and nitric oxide synthase (NOS) gene polymorphisms in type 2 diabetes mellitus,” Antioxidants, vol. 10, no. 4, p. 595, 2021, doi: 10.3390/antiox10040595.
[8] S. Chatterjee, K. Khunti, and M. J. Davies, “Type 2 diabetes,” The Lancet, vol. 389, no. 10085, pp. 2239–2251, 2017.
[9] H. Bashir, S. A. Bhat, S. Majid, R. Hamid, and A. Masood, “Role of inflammatory mediators (TNF-alpha, IL-6, CRP), biochemical and hematological parameters in type 2 diabetes mellitus patients of Kashmir, India,” Medical Journal of Islamic World Academy of Sciences, vol. 28, no. 3, pp. 95–103, 2020, doi: 10.4273/mjimas.28.3.4.
[10] I. R. Musa, O. E. Osman, A. M. Khair, and I. Adam, “The ability of anthropometric indices in detecting type 2 diabetes mellitus in Sudanese adults: A cross-sectional study,” Scientific Reports, vol. 15, p. 29989, 2025, doi: 10.1038/s41598-025-29989-x.
[11] G. M. Reaven, “Insulin resistance: The link between obesity and cardiovascular disease,” Medical Clinics of North America, vol. 95, no. 5, pp. 875–892, 2011.
[12] A. Sirisena and B. Okeahialam, “Association of obesity anthropometric indices with hypertension, diabetes mellitus and hypertriglyceridemia in apparently healthy adult Nigerian population,” World Journal of Cardiology, vol. 14, no. 5, pp. 289–298, 2022, doi: 10.4330/wjc.v14.i5.289.
[13] A. Issaka, A. J. Cameron, Y. Paradies, J. B. Kiwallo, et al., “Associations between obesity indices and both type 2 diabetes and impaired fasting glucose among West African adults: Results from WHO STEPS surveys,” Nutrition, Metabolism and Cardiovascular Diseases, vol. 31, no. 10, pp. 2855–2863, 2021, doi: 10.1016/j.numecd.2021.05.025.
[14] M. D. Sekgala, R. Sewpaul, A. P. Kengne, Z. Mchiza, et al., “Clinical utility of novel anthropometric indices in identifying type 2 diabetes mellitus among South African adult females,” BMC Public Health, vol. 24, p. 20168, 2024, doi: 10.1186/s12889-024-20168-7.
[15] A. I. Bruno, S. Z. Rabiu, O. L. Chinanu, et al., “Anthropometric indices as novel markers of risk in type 2 diabetes mellitus (T2DM) among Nigerian adults in Zamfara State,” Journal of Biological Research and Development, vol. 3, no. 1, pp. 45–56, 2021. [Online]. Available: Journal of Biological Research and Development